3/5
12:53 pm
goss
Gossamer Bio (GOSS) had its price target lowered by Oppenheimer Holdings, Inc. from $12.00 to $3.00. They now have an "outperform" rating on the stock.
Medium
Report
Gossamer Bio (GOSS) had its price target lowered by Oppenheimer Holdings, Inc. from $12.00 to $3.00. They now have an "outperform" rating on the stock.
3/5
09:00 am
goss
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
Medium
Report
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
3/4
06:50 pm
goss
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP
Medium
Report
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP
3/3
04:08 pm
goss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
High
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
3/1
04:07 pm
goss
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
2/26
03:18 pm
goss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
2/26
06:28 am
goss
Gossamer Bio (GOSS) was downgraded by The Goldman Sachs Group, Inc. from "strong-buy" to "hold".
High
Report
Gossamer Bio (GOSS) was downgraded by The Goldman Sachs Group, Inc. from "strong-buy" to "hold".
2/25
06:02 am
goss
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension [Yahoo! Finance]
Medium
Report
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension [Yahoo! Finance]
2/24
08:42 am
goss
Gossamer Bio (NASDAQ:GOSS) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $1.00 price target on the stock.
Medium
Report
Gossamer Bio (NASDAQ:GOSS) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $1.00 price target on the stock.
2/24
07:17 am
goss
Gossamer Bio (NASDAQ:GOSS) was given a new $0.30 price target on by analysts at Barclays PLC.
Low
Report
Gossamer Bio (NASDAQ:GOSS) was given a new $0.30 price target on by analysts at Barclays PLC.
2/24
07:01 am
goss
Gossamer Bio (NASDAQ:GOSS) was upgraded by analysts at Royal Bank Of Canada to an "outperform" rating.
Medium
Report
Gossamer Bio (NASDAQ:GOSS) was upgraded by analysts at Royal Bank Of Canada to an "outperform" rating.
2/24
06:03 am
goss
Gossamer Bio (NASDAQ:GOSS) was downgraded by analysts at Barclays PLC from an "overweight" rating to an "underweight" rating.
Medium
Report
Gossamer Bio (NASDAQ:GOSS) was downgraded by analysts at Barclays PLC from an "overweight" rating to an "underweight" rating.
2/24
04:01 am
goss
Gossamer Bio (NASDAQ:GOSS) was downgraded by analysts at Leerink Partners to a "market perform" rating.
Medium
Report
Gossamer Bio (NASDAQ:GOSS) was downgraded by analysts at Leerink Partners to a "market perform" rating.
2/24
12:01 am
goss
Gossamer Bio (NASDAQ:GOSS) was given a new $1.00 price target on by analysts at Leerink Partners.
Low
Report
Gossamer Bio (NASDAQ:GOSS) was given a new $1.00 price target on by analysts at Leerink Partners.
2/16
01:33 pm
goss
A Look At Gossamer Bio (GOSS) Valuation After Barclays Strong Buy Upgrade And Rising Institutional Ownership [Yahoo! Finance]
Medium
Report
A Look At Gossamer Bio (GOSS) Valuation After Barclays Strong Buy Upgrade And Rising Institutional Ownership [Yahoo! Finance]
2/6
11:12 am
goss
Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation [Yahoo! Finance]
Low
Report
Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation [Yahoo! Finance]
1/29
07:41 am
goss
Gossamer Bio (NASDAQ:GOSS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Medium
Report
Gossamer Bio (NASDAQ:GOSS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
05:02 pm
goss
Gossamer Bio (NASDAQ:GOSS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Medium
Report
Gossamer Bio (NASDAQ:GOSS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/24
12:30 am
goss
Low
Report
1/22
08:06 am
goss
Gossamer Bio (NASDAQ:GOSS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Gossamer Bio (NASDAQ:GOSS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
1/19
08:42 am
goss
Italy on the Move Brings 200+ Italy-US Biotech, Pharma and Investment Leaders Together in San Francisco During JPM Week [Yahoo! Finance]
Low
Report
Italy on the Move Brings 200+ Italy-US Biotech, Pharma and Investment Leaders Together in San Francisco During JPM Week [Yahoo! Finance]
1/8
05:30 pm
goss
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/21
07:51 am
goss
Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data [Yahoo! Finance]
Medium
Report
Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data [Yahoo! Finance]
12/19
05:44 am
goss
Gossamer Bio: High-Risk Binary Approaches [Seeking Alpha]
Low
Report
Gossamer Bio: High-Risk Binary Approaches [Seeking Alpha]
12/9
05:30 pm
goss
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)